3371.F Corbus Pharmaceuticals Holdings, Inc.
- Market cap
- EUR 62.5M
- P/E
- -
- P/B
- 0.52x
- ROE
- -113.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3371.F undervalued?
Graham numberThe Graham number of Corbus Pharmaceuticals Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Corbus Pharmaceuticals Holdings, Inc. fundamental analysis
No fundamental analysis for Corbus Pharmaceuticals Holdings, Inc. yet.
Corbus Pharmaceuticals Holdings, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in No…
Full company profileCorbus Pharmaceuticals Holdings, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Corbus Pharmaceuticals Holdings, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 882K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -56.0M | -34.8M | -45.1M | -48.7M | -85.3M | -121M |
| EBITDA | - | -34.1M | -40.1M | -37.7M | -78.3M | -121M |
| Net Income | -45.6M | -42.3M | -44.6M | -40.2M | -78.5M | -116M |
| EPS | -11 | -10 | -10 | -3.30 | -4.46 | -6.21 |
| Balance Sheet | ||||||
| Total Assets | 108M | 66.3M | 28.3M | 156M | 168M | 127M |
| Total Liabilities | 38.6M | 33.3M | 35.2M | 13.5M | 20.7M | 24.7M |
| Shareholders' Equity | 69.1M | 33.0M | -6.91M | 142M | 148M | 102M |
| Cash & Short-term Investments | 25.0M | 17.0M | 13.7M | 17.2M | 28.5M | 23.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -48.2M | -37.5M | -36.1M | -41.8M | -64.5M | -110M |
| Capital Expenditure | 54.2K | 13.4K | 0.00 | 0.00 | 7.00K | 24.0K |
| Free Cash Flow | -48.2M | -37.6M | -36.1M | -41.8M | -64.5M | -110M |
| Ratios | ||||||
| ROE | -66.0% | -128.4% | - | -28.2% | -53.2% | -113.5% |
| ROA | -42.4% | -63.9% | -157.8% | -25.8% | -46.7% | -91.4% |
| Net Profit Margin | -5,176.4% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Corbus Pharmaceuticals Holdings, Inc. dividends
Corbus Pharmaceuticals Holdings, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:30 on Feb 14, 2023.
Who owns Corbus Pharmaceuticals Holdings, Inc.
- Insiders 1.24%
- Institutions 73.11%
- Public & others 25.66%
- Shares outstanding 19.3M
- Free float 14.1M
Corbus Pharmaceuticals Holdings, Inc. company profile
- Company name
- Corbus Pharmaceuticals Holdings, Inc.
- Ticker
- 3371.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 36
- Fiscal year end
- December
- Address
- 500 River Ridge Drive, Norwood, MA, United States, 02062
- Phone
- 617 963 0100
- Website
- corbuspharma.com
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc. management
7- Dr. Yuval Cohen Ph.D.CEO & Director · born 1975
- Mr. Sean F. Moran CPA, M.B.A.Chief Financial Officer · born 1958
- Dr. Ian Hodgson B.Sc., Ph.D.Chief Operating Officer · born 1973
- Mr. G. Scott Goeken J.D., M.S.General Counsel & Corporate Secretary
- Ms. Christina Bertsch M.A.Vice President of Human Resources
- Mr. Nishant C. SaxenaChief Business Officer
- Dr. Leonardo Viana Nicacio M.D.Chief Medical Officer · born 1978